Centers for Medicare & Medicaid Services Extend Contract with MAXIMUS

Release Date: Tuesday, February 23, 2010 6:30 am EST

Terms: Contracts and Awards

Dateline City: RESTON, Va.

MAXIMUS Federal to Continue Independent Medicare Part D Review Work

RESTON, Va.--(BUSINESS WIRE)--MAXIMUS (NYSE:MMS), a leading provider of government services worldwide, announced today that its Federal Services subsidiary has been awarded a one-year contract by the Centers for Medicare & Medicaid Services (CMS) to continue to serve as an independent review entity for reconsiderations of beneficiary appeals for the Medicare Part D program. The Company has performed this work since the Medicare prescription drug program was implemented in January 2006. The one-year contract is valued at approximately $14.3 million and includes a nine-month option period, which brings the total contract value to $25.0 million if this option is exercised.

As the Part D Qualified Independent Contractor (QIC), MAXIMUS Federal acts as the independent review entity responsible for conducting reconsiderations of adverse coverage determinations and redeterminations made by Part D plans in the Medicare Prescription Drug Program. Under the current contract, MAXIMUS Federal also conducts reconsiderations of adverse determinations related to prior creditable prescription drug coverage and imposition of a late enrollment penalty under the Medicare Part D program. In addition to Medicare Part D, MAXIMUS Federal also performs reconsiderations nationally as Part A and Part C QICs.

“MAXIMUS is committed to providing unrivaled service in the administration of government health and human services programs as we seek to expand our client relationships,” commented MAXIMUS CEO Richard Montoni. “MAXIMUS Federal has been the sole provider of Part D appeal reconsiderations since the inception of the Medicare Part D program. This latest contract award from CMS underscores our role as a leading QIC and allows us the opportunity to process Medicare Part D reconsiderations across the entire country.”

In addition, MAXIMUS Federal is also recognized as the industry leader for government-sponsored health reconsideration and appeals programs at the state level, and operates clinical review projects for 30 state regulatory agencies. With over 200 health reconsideration experts across the Company, MAXIMUS delivers experience and thought leadership to the critical process of health appeals reconsiderations. MAXIMUS Federal provides specialized services through a blend of professionals, including physicians, pharmacists, and attorneys, who are able to navigate the challenging and often complex regulations encompassing health reconsiderations and appeals.

MAXIMUS Federal Services is fully accredited by the Utilization Review Accreditation Commission as an independent review organization. Many of the Company’s independent review programs are also ISO 9001:2008 certified. Since 1989, MAXIMUS has completed more than 750,000 reconsiderations.

About MAXIMUS

MAXIMUS is a leading provider of government services worldwide and is devoted to providing health and human services program management and consulting services to its clients. The Company has more than 6,500 employees located in more than 220 offices in the United States, Canada, Australia, the United Kingdom, and Israel. Additionally, MAXIMUS is included in the Russell 2000 Index and the S&P SmallCap 600 Index.

Language: English

Contact:
MAXIMUS
Lisa Miles, 800-MAXIMUS x11637

Ticker Slug:
Ticker: MMS
Exchange: NYSE

Source URL: https://investor.maximus.com/press-release/contracts-and-awards/centers-medicare-medicaid-services-extend-